If ATM inhibitors do not radiosensitize TP53-wild-type tumors as predicted by our studies, then the primary brainstem gliomas driven by PTEN pathway alterations with wild-type TP53 can be used to search for alternative therapeutic approaches to radiosensitize tumors with this genotype. The gene discussed is TP53; the disease is brain stem glioma.